Omnicell (NASDAQ:OMCL) Cut to Hold at StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a report released on Tuesday morning.

A number of other equities analysts have also recently issued reports on OMCL. Wells Fargo & Company lifted their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum lifted their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Barclays lifted their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America reiterated a “neutral” rating and set a $57.00 price target (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $52.00.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $45.96 on Tuesday. The company has a market cap of $2.13 billion, a P/E ratio of -117.85, a PEG ratio of 34.95 and a beta of 0.77. Omnicell has a one year low of $25.12 and a one year high of $55.74. The business’s 50-day simple moving average is $45.25 and its 200 day simple moving average is $38.90.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its stake in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the period. GAMMA Investing LLC boosted its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares during the period. CWM LLC boosted its stake in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares during the period. 1620 Investment Advisors Inc. boosted its stake in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Omnicell in the second quarter valued at approximately $104,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.